BioSenic announces partnership with 4Moving Biotech to join forces to codevelop 4P004v, first-in-class GLP-1-based disease modifying drug for post-ligament surgery in dogs and the securing of its financing for the coming months by means of an amendment to its convertible bonds agreement.
Date
Year
Filter Criteria
Document Upload
BIOS_PR_20250630_EN_final.pdf346.47 KB
